7-Methoxy-naphthalene-2-sulfonic acid [(S)-1-(1,6-diamino-isoquinolin-7-ylmethyl)-2-oxo-pyrrolidin-3-yl]-amide

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 7-Methoxy-naphthalene-2-sulfonic acid [(S)-1-(1,6-diamino-isoquinolin-7-ylmethyl)-2-oxo-pyrrolidin-3-yl]-amide
• 英文别名: N-[(3S)-1-[(1,6-diaminoisoquinolin-7-yl)methyl]-2-oxopyrrolidin-3-yl]-7-methoxynaphthalene-2-sulfonamide
• 化学式: C₂₅H₂₅N₅O₄S
• 分子量: 491.571
• InChiKey: NKKBRPCGZZKXSN-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  149
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  benzhydrylidene-(7-bromomethyl-1-chloro-isoquinolin-6-yl)-amine 在 盐酸 、 ammonium acetate 、 sodium hydride 、 三乙胺 、 苯酚 作用下， 以 四氢呋喃 、 乙酸乙酯 、 乙腈 为溶剂， 生成 7-Methoxy-naphthalene-2-sulfonic acid [(S)-1-(1,6-diamino-isoquinolin-7-ylmethyl)-2-oxo-pyrrolidin-3-yl]-amide
  参考文献：
  名称：

  Aminoisoquinolines: Design and synthesis of an orally active benzamidine isostere for the inhibition of factor XA

  摘要：

  The design, synthesis and SAR of sulfonamidopyrrolidinone, fXa inhibitors incorporating a new benzamidine isostere, namely aminoisoquinolines, is described. These inhibitors have higher Caco-2 cell permeability than comparable benzamidines and attain higher levels of exposure upon oral dosing. The most potent member 14b (fXa Ki=6 nM) is selective against other serine proteases of interest (>600 fold). (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00421-7

文献信息

• SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS
  申请人：RHONE-POULENC RORER PHARMACEUTICALS, INC.

  公开号：EP0944386A1

  公开（公告）日：1999-09-29
• EP0944386A4
  申请人：——

  公开号：EP0944386A4

  公开（公告）日：2001-04-11
• [EN] SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS<br/>[FR] COMPOSES A BASE D'ACIDE SULFONIQUE OU DE SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE
  申请人：——

  公开号：WO1998025611A1

  公开（公告）日：1998-06-18

  [EN] The compounds of formula (I) herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula (I), compositions containing compounds of formula (I), and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.
  [FR] Les composés représentés par la formule (I) possèdent une activité pharmacologique utile et sont par conséquent incorporés à des compositions pharmaceutiques et utilisés pour le traitement de patients souffrant de certains troubles pathologiques. Plus spécifiquement, ces composés sont des inhibiteurs de l'activité du facteur Xa. La présente invention se rapporte à des composés représentés par la formule (I), à des compositions contenant des composés de formule (I), ainsi qu'à leur utilisation s'agissant du traitement d'un patient souffrant d'une affection physiologique ou sujet à une telle affection, ladite affection pouvant être améliorée par l'administration d'un inhibiteur de l'activité du facteur Xa.
• Aminoisoquinolines: Design and synthesis of an orally active benzamidine isostere for the inhibition of factor XA
  作者：Y.M. Choi-Sledeski、M.R. Becker、D.M. Green、R. Davis、W.R. Ewing、H.J. Mason、C. Ly、A. Spada、G. Liang、D. Cheney、J. Barton、V. Chu、K. Brown、D. Colussi、R. Bentley、R. Leadley、C. Dunwiddie、H.W. Pauls

  DOI：10.1016/s0960-894x(99)00421-7

  日期：1999.9

  The design, synthesis and SAR of sulfonamidopyrrolidinone, fXa inhibitors incorporating a new benzamidine isostere, namely aminoisoquinolines, is described. These inhibitors have higher Caco-2 cell permeability than comparable benzamidines and attain higher levels of exposure upon oral dosing. The most potent member 14b (fXa Ki=6 nM) is selective against other serine proteases of interest (>600 fold). (C) 1999 Elsevier Science Ltd. All rights reserved.